Can Pth Reverse Glucocorticoid Induced Osteoporosis?

Lane, Nancy E.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Type: Research Project (R01)
• Project #: 5R01DK046661-02
• Application #: 2145937
• Study Section: Orthopedics and Musculoskeletal Study Section (ORTH)
• Project Start: 1995-02-22
• Project End: 1997-12-31
• Budget Start: 1996-02-10
• Budget End: 1996-12-31
• Support Year: 2
• Fiscal Year: 1996

Institution

• Name: University of California San Francisco
• Department: Internal Medicine/Medicine
• Type: Schools of Medicine
• DUNS #: 073133571
• City: San Francisco
• State: CA
• Country: United States
• Zip Code: 94143

Publications

Balooch, Guive; Yao, Wei; Ager, Joel W et al. (2007) The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of glucocorticoids. Arthritis Rheum 56:3726-37

Lane, Nancy E; Yao, Wei; Balooch, Mehdi et al. (2006) Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 21:466-76

Hurley, Marja; Yao, Wei; Lane, Nancy E (2005) Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). Osteoporos Int 16:2080-4

Buxton, Eric C; Yao, Wei; Lane, Nancy E (2004) Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab 89:3332-6

Thompson, J M; Modin, G W; Arnaud, C D et al. (1997) Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: predictors of bone mineral density. Calcif Tissue Int 61:377-81